Mylotte Darren, Osnabrugge Ruben Lj, Martucci Giuseppe, Lange Ruediger, Kappetein Arie Pieter, Piazza Nicolo
Department of Interventional Cardiology, McGill University Health Centre, Montreal, Quebec, Canada.
Department of Cardiology, University Hospital Galway, Galway, Ireland.
Interv Cardiol. 2014 Mar;9(1):37-40. doi: 10.15420/icr.2011.9.1.37.
Transcatheter aortic valve implantation (TAVI) is a novel therapeutic option for patients with severe symptomatic aortic stenosis (AS) at excessive or high surgical risk for conventional surgical aortic valve replacement. First commercialised in Europe in 2007, TAVI growth has been exponential among some Western European nations, though recent evidence suggests heterogeneous adoption of this new and expensive therapy. Herein, we review the evidence describing the utilisation of TAVI in Western Europe.
经导管主动脉瓣植入术（TAVI）是一种针对有严重症状的主动脉瓣狭窄（AS）患者的新型治疗选择，这些患者接受传统外科主动脉瓣置换手术的风险过高或处于高位。2007年TAVI在欧洲首次商业化，在一些西欧国家，TAVI的增长呈指数级，不过最近的证据表明这种新的昂贵治疗方法的采用情况并不一致。在此，我们回顾描述TAVI在西欧使用情况的证据。
